345 related articles for article (PubMed ID: 18372278)
21. Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.
Davie AP; Rumley A; Lowe GD; McMurray JJ
Thromb Haemost; 2001 Dec; 86(6):1585-6. PubMed ID: 11776334
[No Abstract] [Full Text] [Related]
22. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
Boman KO; Jansson JH; Nyhlén KA; Nilsson TK
Thromb Haemost; 2002 Feb; 87(2):311-6. PubMed ID: 11859853
[TBL] [Abstract][Full Text] [Related]
23. Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
Moriyama Y; Ogawa H; Oshima S; Arai H; Takazoe K; Shimomura H; Hirai N; Suefuji H; Soejima H; Nishiyama K; Misumi K; Yasue H
Coron Artery Dis; 1998; 9(10):691-6. PubMed ID: 9894621
[TBL] [Abstract][Full Text] [Related]
24. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits.
Schuh JR; Blehm DJ; Frierdich GE; McMahon EG; Blaine EH
J Clin Invest; 1993 Apr; 91(4):1453-8. PubMed ID: 8473494
[TBL] [Abstract][Full Text] [Related]
26. Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in healthy subjects.
Lottermoser K; Hertfelder HJ; Wehling M; Schiermeyer B; Vetter H; Düsing R
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):357-60. PubMed ID: 11967823
[TBL] [Abstract][Full Text] [Related]
27. Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients.
Trošt Rupnik A; Pajek J; Guček A; Osredkar J; Kovač D; Bren A; Klančič D; Saksida S; Rus I; Globokar M; Drozg A; Lešnik M; Plešivčnik Z; Ekart R; Lopert S; Lindič J
Ther Apher Dial; 2013 Aug; 17(4):425-30. PubMed ID: 23931884
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats.
Gromotowicz-Poplawska A; Stankiewicz A; Mikita J; Aleksiejczuk M; Marcinczyk N; Szemraj J; Chabielska E
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980144
[TBL] [Abstract][Full Text] [Related]
30. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
Brown NJ; Agirbasli MA; Williams GH; Litchfield WR; Vaughan DE
Hypertension; 1998 Dec; 32(6):965-71. PubMed ID: 9856958
[TBL] [Abstract][Full Text] [Related]
31. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Goodfield NE; Newby DE; Ludlam CA; Flapan AD
Circulation; 1999 Jun; 99(23):2983-5. PubMed ID: 10368114
[TBL] [Abstract][Full Text] [Related]
32. [Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension].
Martyniuk TV; Chazova IE; Masenko VP; Volkov VN; Belenkov IuN
Ter Arkh; 1998; 70(4):33-6. PubMed ID: 9612899
[TBL] [Abstract][Full Text] [Related]
33. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
[TBL] [Abstract][Full Text] [Related]
34. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
[TBL] [Abstract][Full Text] [Related]
35. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
Agirbasli M; Cincin A; Baykan OA
J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
[TBL] [Abstract][Full Text] [Related]
36. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
37. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
38. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
[TBL] [Abstract][Full Text] [Related]
39. The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters.
Kaşifoğlu T; Yalçin AU
Anadolu Kardiyol Derg; 2006 Jun; 6(2):143-7. PubMed ID: 16766279
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacology of enalapril.
Abrams WB; Davies RO; Gomez HJ
J Hypertens Suppl; 1984 Dec; 2(2):S31-6. PubMed ID: 6100874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
